Abstract
The clinical differences between oxcarbazepine (OXC) and carbamazepine (CBZ) are reviewed in terms of efficacy, tolerability, and interaction with other drugs in a study at Universitat Bonn, Berlin, Germany.
Highlights
OXC metabolizes by reduction to the monohydroxy derivative (MHD) and is excreted in the urine after conjugation as a glucuronide, with no autoinduction
Pediatric Neurology Briefs 2004 dose of 20 mg/kg/day provided a >75% reduction in partial seizures in 84% patients, and 100% reduction in 60%. (Report of responses from neurologists provided by Bergman S, Novartis)
Sixty-one percent of neurologists were already using Trileptal as monotherapy for partial seizures in children ages 4-16, and 68% use it as adjunctive therapy
Summary
The clinical differences between oxcarbazepine (OXC) and carbamazepine (CBZ) are reviewed in terms of efficacy, tolerability, and interaction with other drugs in a study at Universitat Bonn, Berlin, Germany. OXC (Trileptal) is used as monotherapy or adjunctive therapy for the treatment of partial seizures with or without secondary generalization in adults and children above 4 years (USA) or 6 years (Europe) of age. OXC is better tolerated and its risk-benefits are superior to CBZ.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
